Extracellular Vesicles from Pancreatic Cancer Stem Cells Lead an Intratumor Communication Network (EVNet) to fuel tumour progression
Year: 2022
Type: article
Abstract: Objective Intratumor heterogeneity drives cancer progression and therapy resistance. However, it has yet to be determined whether and how subpopulations of cancer cells interact and how this interaction affects the tumour. Design We have studied the spontaneous flow of extracellular vesicles (EVs) between subpopulations of cancer cells: cancer stem cells (CSC) and non-stem cancer cells (NSCC). To determine the biological significance of the most frequent communication route, we used pancreatic ductal adenocarcinoma (PDAC) orthotopic models, patient-derived xenografts (PDXs) and genetically engineered mouse models (GEMMs). Results We demonstrate that PDAC tumours establish an organised communication network between subpopulations of cancer cells using EVs called the EVNet). The EVNet is plastic and reshapes in response to its environment. Communication within the EVNet occurs preferentially from CSC to NSCC. Inhibition of this communication route by impairing Rab27a function in orthotopic xenographs, GEMMs and PDXs is sufficient to hamper tumour growth and phenocopies the inhibition of communication in the whole tumour. Mechanistically, we provide evidence that CSC EVs use agrin protein to promote Yes1 associated transcriptional regulator (YAP) activation via LDL receptor related protein 4 (LRP-4). Ex vivo treatment of PDXs with antiagrin significantly impairs proliferation and decreases the levels of activated YAP. Patients with high levels of agrin and low inactive YAP show worse disease-free survival. In addition, patients with a higher number of circulating agrin + EVs show a significant increased risk of disease progression. Conclusion PDAC tumours establish a cooperation network mediated by EVs that is led by CSC and agrin, which allows tumours to adapt and thrive. Targeting agrin could make targeted therapy possible for patients with PDAC and has a significant impact on CSC that feeds the tumour and is at the centre of therapy resistance.
Source: Gut
Authors: Carolina F Ruivo, Nuno Bastos, Barbara Adem, Ines Batista, Cecilia Duraes, Carlos A Melo, Stephanie A Castaldo, Francisco Campos‐Laborie, Pedro Moutinho-Ribeiro, Barbara Morão, Ana Costa-Pinto, Soraia Silva, Hugo Osorio, Sergio Ciordia, Jose Luis Costa, David Goodrich, Bruno Cavadas, Luisa Pereira, Tony Kouzarides, Guilherme Macedo, Rui Maio, Fatima Carneiro, Marília Cravo, Raghu Kalluri, Jose Carlos Machado, Sonia A Melo
Institutions: Universidade do Porto, i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Instituto de Ciências Biomédicas Albel Salazar, The Gurdon Institute, VIB-KU Leuven Center for Cancer Biology, Hospital de São João, Hospital Beatriz Ângelo, Centro Nacional de Biotecnología, Roswell Park Comprehensive Cancer Center, Hospital da Luz, Universidade Nova de Lisboa, University of Lisbon, The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: hybrid
Awards: Exploiting RB1 deficiency for the treatment of lethal neuroendocrine prostate cancer, G1314954773, G1452531853, G1516346500, G1763632427, G1830165626, G2061926898, G2195151728, G2427613718, NOTCH signaling controls transformation to androgen independent neuroendocrine prostate cancer, G2964751290, G323769159, ExoCanCell: The impact of exosomes biogenesis impairment in pancreatic cancer progression and therapy response, G3840324753, PancExoNet: The role of exosomes-mediated communication in pancreatic cancer progression, (PQB5) Does the timing of Pten and Rb1 mutation affect prostate cancer phenotypes, G4316116677, Novo: Deconstructing the Immune Response in PDAC progression. Incicial: SHUSH CANCER CELLS – IMMUNOTHERAPY becoming a reality for PDAC PATIENTS, G4724859719, G5224927334, G5350179487, G5454278309, G5485649731, G5677667711, G6372545043, G6930629665, G7105264150, G7584003722, G7923443948, G7965899483, G8316263078, ExoBow: The Spatiotemporal biodistribution of pancreatic cancer exosomes, G862925997, Cancer Center Support Grant, Coordinating and Data Management Center for Acquired Resistance to Therapy Network, G96847669
OpenAlex ID: W4206609166
